Tyrosine phosphorylation: thirty years and counting
- PMID: 19269802
- PMCID: PMC2670436
- DOI: 10.1016/j.ceb.2009.01.028
Tyrosine phosphorylation: thirty years and counting
Abstract
In the 30 years since its discovery, tyrosine phosphorylation has emerged as a fundamentally important mechanism of signal transduction and regulation in all eukaryotic cells, governing many processes, including cell proliferation, cell cycle progression, metabolic homeostasis, transcriptional activation, neural transmission, differentiation and development, and aging. Perturbations in tyrosine phosphorylation underlie many human diseases, and in particular cancer, and this has prompted the development of inhibitors of tyrosine kinases implicated in disease, a number of which have been approved for clinical use. The following is a brief personal reflection on some of the salient findings over the past 30 years that led to the development of tyrosine kinase inhibitors for disease therapy.
Figures
Similar articles
-
Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.Curr Drug Discov Technol. 2020;17(5):585-615. doi: 10.2174/1570163816666190808120843. Curr Drug Discov Technol. 2020. PMID: 31393251 Review.
-
The role of tyrosine phosphorylation in cell growth and disease.Harvey Lect. 1998-1999;94:81-119. Harvey Lect. 1998. PMID: 11070953 Review. No abstract available.
-
Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models.Curr Med Chem. 2011;18(19):2836-47. doi: 10.2174/092986711796150513. Curr Med Chem. 2011. PMID: 21651495 Review.
-
Advances in studies of tyrosine kinase inhibitors and their acquired resistance.Mol Cancer. 2018 Feb 19;17(1):36. doi: 10.1186/s12943-018-0801-5. Mol Cancer. 2018. PMID: 29455664 Free PMC article. Review.
-
DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.Pharmacol Ther. 2015 Jul;151:87-98. doi: 10.1016/j.pharmthera.2015.03.004. Epub 2015 Mar 17. Pharmacol Ther. 2015. PMID: 25795597 Review.
Cited by
-
Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function.Genes Cancer. 2012 Nov;3(11-12):619-33. doi: 10.1177/1947601912473305. Genes Cancer. 2012. PMID: 23634251 Free PMC article.
-
Non-Muscle Myosin 2A (NM2A): Structure, Regulation and Function.Cells. 2020 Jul 1;9(7):1590. doi: 10.3390/cells9071590. Cells. 2020. PMID: 32630196 Free PMC article. Review.
-
Magnesium induced structural reorganization in the active site of adenylate kinase.Sci Adv. 2024 Aug 9;10(32):eado5504. doi: 10.1126/sciadv.ado5504. Epub 2024 Aug 9. Sci Adv. 2024. PMID: 39121211 Free PMC article.
-
Cellular Site-Specific Incorporation of Noncanonical Amino Acids in Synthetic Biology.Chem Rev. 2024 Sep 25;124(18):10577-10617. doi: 10.1021/acs.chemrev.3c00938. Epub 2024 Aug 29. Chem Rev. 2024. PMID: 39207844 Review.
-
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors.J Vis Exp. 2020 Jul 17;(161):10.3791/61457. doi: 10.3791/61457. J Vis Exp. 2020. PMID: 32744526 Free PMC article.
References
-
- Eckhart W, Hutchinson MA, Hunter T. An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates. Cell. 1979;18:925–933. - PubMed
-
- Hunter T, Eckhart W. The discovery of tyrosine phosphorylation: it’s all in the buffer! Cell. 2004;116:S35–39. - PubMed
-
- Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell. 2004;116:191–203. - PubMed
-
-
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–1934.. This paper describes the first complete catalogue of human protein kinases, and defines the set of 90 tyrosine kinases encoded by the human genome.
-
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous